Vorapaxar CAS NO 618385-01-6 Inquire about Vorapaxar

Tecoland supplies Vorapaxar bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Vorapaxar is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Vorapaxar?

Vorapaxar (brand name Zontivity, formerly known as SCH 530348) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist based on the natural product himbacine, discovered by Schering-Plough and developed by Merck & Co.

What is Vorapaxar used for?

Vorapaxar is used for persons with a history of myocardial infarction (heart attack) or persons with peripheral arterial disease. Studies have shown that this medication can reduce the rate of combined endpoint cardiovascular death, MI, stroke, and urgent coronary revascularization.

Dosa adjustment of Vorapaxar:

No dose adjustment is required in persons with renal impairment. No dose adjustment is required in persons with mild and moderate hepatic impairment. If the person has severe hepatic impairment, vorapaxar is not recommended due to the risk of bleeding.

Mechanism of Action:

Vorapaxar is a new anti-platelet drug that is part of the PAR-1 antagonist family, a new class of anti-platelet drug. It functions by inhibiting thrombin-related platelet aggregation. This mechanism works by a different pathway than other anti-platelet medications such as aspirin and P2Y12 inhibitors. Unlike many other medication, vorapaxar does not affect ADP-mediated platelet aggregation, coagulation parameters, or bleeding time.

Vorapaxar Drug Interactions:

Vorapaxar is eliminated primarily by metabolism by CYP3A enzymes. It is best to avoid any strong CYP3A4 inhibitors(ex: ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin, and conivaptan). CYP3A4 inducers(Carbamazepine, rifampin, St.John’s Wort, and Phenytoin) should also be avoided. On May 5, 2014, vorapaxar obtained FDA approval.

Vorapaxar Side effects:

● a light-headed feeling, like you might pass out;
● easy bruising or bleeding (nosebleeds, bleeding gums);
● red or brown urine, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
● any bleeding that will not stop;

Storage

Vorapaxar can be stored at 20-25°C(68-77°F). It is best to store vorapaxar in original packaging with the bottle tightly closed and to avoid moisture.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.